Neuphoria Therapeutics Inc.
Datakwaliteit: 100%
NEUP
Nasdaq
Manufacturing
Chemicals
€ 4,61
▼
€ 0,09
(-1,91%)
Marktkapitalisatie: 24,85 M
Prijs
€ 4,61
Marktkapitalisatie
24,85 M
Dagbereik
€ 4,57 — € 4,73
52-Weeksbereik
€ 3,65 — € 21,40
Volume
41.265
Openen € 4,73
50D / 200D Gem.
€ 4,28
7,71% above
50D / 200D Gem.
€ 6,87
32,86% below
Quick Summary
Belangrijkste Punten
Generating 77.229,0 in free cash flow
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-1,33%
Boven sectorgemiddelde (-53,41%)
ROIC-2,82%
Net Margin-2,36%
Op. Margin-7,21%
Veiligheid
Debt / Equity
N/A
Current Ratio11,01
Interest CoverageN/A
Waardering
PE (TTM)
-67,23
Onder sectorgemiddelde (-1,48)
P/B Ratio0,96
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -67,2 | -1,5 |
| P/B | 1,0 | 1,6 |
| ROE % | -1,3 | -53,4 |
| Net Margin % | -2,4 | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
ETFs Holding This Stock
4,03% weight
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 15,65 M | Net Income (TTM) | -369.632,0 |
| ROE | -1,33% | ROA | -1,10% |
| Gross Margin | N/A | Operating Margin | -7,21% |
| Net Margin | -2,36% | Free Cash Flow (TTM) | 77.229,0 |
| ROIC | -2,82% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 11,01 |
| Interest Coverage | N/A | Asset Turnover | 0,47 |
| Working Capital | 15,54 M | Tangible Book Value | 12,58 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -67,23 | Forward P/E | N/A |
| P/B Ratio | 0,96 | P/S Ratio | 1,59 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 0,31% | ||
| Market Cap | 24,85 M | Enterprise Value | 7,81 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,23 | Revenue / Share | 2,90 |
| FCF / Share | 0,01 | OCF / Share | 0,01 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | -20,89% |
| SBC-Adj. FCF | -86.543 | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | 15,65 M | — |
| Net Income | -369.632,0 | -15,49 M |
| EPS (Diluted) | -0,23 | -0,01 |
| Gross Profit | — | — |
| Operating Income | -1,13 M | -17,89 M |
| EBITDA | — | — |
| R&D Expenses | 9,01 M | 9,42 M |
| SG&A Expenses | — | — |
| D&A | 662.890,0 | 662.991,0 |
| Interest Expense | — | — |
| Income Tax | -468.366,0 | -87.320,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Total Assets | 28,59 M | 27,65 M |
| Total Liabilities | 9,59 M | 10,16 M |
| Shareholders' Equity | 19,00 M | 17,49 M |
| Total Debt | — | — |
| Cash & Equivalents | 14,21 M | 12,61 M |
| Current Assets | 15,04 M | 13,19 M |
| Current Liabilities | 4,22 M | 3,83 M |
{"event":"ticker_viewed","properties":{"ticker":"NEUP","listing_kind":"stock","pathname":"/stocks/neup","exchange":"Nasdaq","country":"US"}}